Oligoclonal Expansions of Specific TcR-Vβs by Spectratype Analysis
| Patient No. . | Pretransplant . | 1-2 Mo . | 3-5 Mo . | 6-12 Mo . | ||||
|---|---|---|---|---|---|---|---|---|
| TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | |
| 1 | — | — | — | Vβ 16 | 62% (1) | |||
| 2 | Vβ 3 | 64% (1) | Vβ 4 | 94% (1) | Vβ 1 | 95% (1) | Vβ 4 | 77% (1) |
| Vβ 5.1 | 100% (1) | Vβ 4 | 66% (1) | Vβ 5.2 | 100% (2) | |||
| Vβ 8 | 77% (1) | Vβ 12 | 66% (1) | Vβ 11.2 | 85% (2) | |||
| Vβ 11.2 | 88% (2) | Vβ 13.5 | 67% (1) | Vβ 16 | 87% (1) | |||
| Vβ 14 | 99% (1) | Vβ 16 | 98% (1) | Vβ 20 | 75% (1) | |||
| Vβ 16 | 100% (1) | Vβ 20 | 69% (1) | Vβ 24 | 100% (2) | |||
| 3 | ND | ND | ||||||
| 4 | — | — | — | Vβ 2 | 90% (2) | |||
| Vβ 25 | 92% (1) | |||||||
| 5 | — | Vβ 1 | 68% (1) | ND | ND | |||
| Vβ 8 | 100% (2) | |||||||
| Vβ 14 | 100% (2) | |||||||
| Vβ 21 | 100% (1) | |||||||
| 6 | Vβ 24 | 100% (2) | — | Vβ 8 | 66% (1) | Vβ 25 | 95% (1) | |
| Vβ 25 | 100% (1) | Vβ 9 | 73% (1) | |||||
| Vβ 25 | 98% (1) | |||||||
| 7 | — | Vβ 3 | 100% (1) | — | — | |||
| Vβ 6 | 100% (1) | |||||||
| Vβ 16 | 79% (1) | |||||||
| Vβ 17 | 71% (1) | |||||||
| Vβ 18 | 96% (2) | |||||||
| Vβ 25 | 100% (1) | |||||||
| 8 | — | Vβ 5.2 | 82% (2) | ND | ND | |||
| Vβ 7.5 | 96% (2) | |||||||
| Vβ 25 | 76% (1) | |||||||
| Patient No. . | Pretransplant . | 1-2 Mo . | 3-5 Mo . | 6-12 Mo . | ||||
|---|---|---|---|---|---|---|---|---|
| TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | TcR-V . | % (no. of peaks) . | |
| 1 | — | — | — | Vβ 16 | 62% (1) | |||
| 2 | Vβ 3 | 64% (1) | Vβ 4 | 94% (1) | Vβ 1 | 95% (1) | Vβ 4 | 77% (1) |
| Vβ 5.1 | 100% (1) | Vβ 4 | 66% (1) | Vβ 5.2 | 100% (2) | |||
| Vβ 8 | 77% (1) | Vβ 12 | 66% (1) | Vβ 11.2 | 85% (2) | |||
| Vβ 11.2 | 88% (2) | Vβ 13.5 | 67% (1) | Vβ 16 | 87% (1) | |||
| Vβ 14 | 99% (1) | Vβ 16 | 98% (1) | Vβ 20 | 75% (1) | |||
| Vβ 16 | 100% (1) | Vβ 20 | 69% (1) | Vβ 24 | 100% (2) | |||
| 3 | ND | ND | ||||||
| 4 | — | — | — | Vβ 2 | 90% (2) | |||
| Vβ 25 | 92% (1) | |||||||
| 5 | — | Vβ 1 | 68% (1) | ND | ND | |||
| Vβ 8 | 100% (2) | |||||||
| Vβ 14 | 100% (2) | |||||||
| Vβ 21 | 100% (1) | |||||||
| 6 | Vβ 24 | 100% (2) | — | Vβ 8 | 66% (1) | Vβ 25 | 95% (1) | |
| Vβ 25 | 100% (1) | Vβ 9 | 73% (1) | |||||
| Vβ 25 | 98% (1) | |||||||
| 7 | — | Vβ 3 | 100% (1) | — | — | |||
| Vβ 6 | 100% (1) | |||||||
| Vβ 16 | 79% (1) | |||||||
| Vβ 17 | 71% (1) | |||||||
| Vβ 18 | 96% (2) | |||||||
| Vβ 25 | 100% (1) | |||||||
| 8 | — | Vβ 5.2 | 82% (2) | ND | ND | |||
| Vβ 7.5 | 96% (2) | |||||||
| Vβ 25 | 76% (1) | |||||||
Single peaks comprising greater than 60% of the total peak height or double peaks each comprising greater than 40% of the total peak height were included as oligoclonal populations. The percentage of total peak amplitude contained within single peak (1) or within two peaks (2) is shown. Data were only acquired at 1 month after transplantation for patients 3 and 5.
Abbreviation: ND, not determined.